FindTrial
Sign In

To assess the consistency of peripheral blood and bone marrow gene expression in patients with low- and medium-risk acute myeloid leukemia who are positive for AML1/ETO or CBF?-MYH11 after remission

To assess the consistency of peripheral blood and bone marrow gene expression in patients with low- and medium-risk acute myeloid leukemia who are positive for AML1/ETO or CBF?-MYH11 after remission

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049945
Enrollment
Unknown
Registered
2021-08-14
Start date
2021-08-03
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

Group A:AML1/ETO or CBF ß-MYH11 negative
Group B:AML1/ETO or CBF a-MYH11 negative

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with low- and medium-risk AML treated in the First Affiliated Hospital of Zhengzhou University (diagnostic stratification according to the Chinese Diagnostic Guidelines for Adult AML (2017)) and positive for AML1/ETO or CBF?-MYH11 gene at the first diagnosis.

Exclusion criteria

Exclusion criteria: No.

Design outcomes

Primary

MeasureTime frame
AML1/ETO or CBFß-MYH11 were detected by PCR;—

Countries

China

Contacts

Public ContactHan Lijie

The First Affiliated Hospital of Zhengzhou University

hanlijiede@126.com+86 18703809807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026